Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/USP1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/USP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/USP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/USP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/USP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/USP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006032616 | Thyroid | HT | cell chemotaxis | 40/1272 | 310/18723 | 6.97e-05 | 1.27e-03 | 40 |
GO:200027824 | Thyroid | HT | regulation of DNA biosynthetic process | 19/1272 | 106/18723 | 8.68e-05 | 1.48e-03 | 19 |
GO:00512718 | Thyroid | HT | negative regulation of cellular component movement | 45/1272 | 367/18723 | 8.73e-05 | 1.48e-03 | 45 |
GO:20001468 | Thyroid | HT | negative regulation of cell motility | 44/1272 | 359/18723 | 1.05e-04 | 1.75e-03 | 44 |
GO:005159126 | Thyroid | HT | response to cAMP | 17/1272 | 93/18723 | 1.57e-04 | 2.39e-03 | 17 |
GO:00719015 | Thyroid | HT | negative regulation of protein serine/threonine kinase activity | 20/1272 | 120/18723 | 1.62e-04 | 2.43e-03 | 20 |
GO:00400138 | Thyroid | HT | negative regulation of locomotion | 46/1272 | 391/18723 | 1.94e-04 | 2.84e-03 | 46 |
GO:007190019 | Thyroid | HT | regulation of protein serine/threonine kinase activity | 43/1272 | 359/18723 | 2.09e-04 | 3.01e-03 | 43 |
GO:00380668 | Thyroid | HT | p38MAPK cascade | 12/1272 | 55/18723 | 2.62e-04 | 3.63e-03 | 12 |
GO:00303368 | Thyroid | HT | negative regulation of cell migration | 41/1272 | 344/18723 | 3.22e-04 | 4.21e-03 | 41 |
GO:003059516 | Thyroid | HT | leukocyte chemotaxis | 30/1272 | 230/18723 | 4.46e-04 | 5.45e-03 | 30 |
GO:004340925 | Thyroid | HT | negative regulation of MAPK cascade | 25/1272 | 180/18723 | 5.10e-04 | 6.14e-03 | 25 |
GO:00703718 | Thyroid | HT | ERK1 and ERK2 cascade | 39/1272 | 330/18723 | 5.27e-04 | 6.31e-03 | 39 |
GO:004668320 | Thyroid | HT | response to organophosphorus | 20/1272 | 131/18723 | 5.34e-04 | 6.38e-03 | 20 |
GO:009752917 | Thyroid | HT | myeloid leukocyte migration | 28/1272 | 220/18723 | 9.99e-04 | 1.02e-02 | 28 |
GO:19007445 | Thyroid | HT | regulation of p38MAPK cascade | 10/1272 | 47/18723 | 1.03e-03 | 1.05e-02 | 10 |
GO:000268518 | Thyroid | HT | regulation of leukocyte migration | 27/1272 | 210/18723 | 1.05e-03 | 1.06e-02 | 27 |
GO:005090017 | Thyroid | HT | leukocyte migration | 41/1272 | 369/18723 | 1.31e-03 | 1.26e-02 | 41 |
GO:001063925 | Thyroid | HT | negative regulation of organelle organization | 39/1272 | 348/18723 | 1.45e-03 | 1.36e-02 | 39 |
GO:000716218 | Thyroid | HT | negative regulation of cell adhesion | 34/1272 | 303/18723 | 2.76e-03 | 2.27e-02 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP1 | SNV | Missense_Mutation | | c.1516N>A | p.Cys506Ser | p.C506S | O94782 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
USP1 | SNV | Missense_Mutation | | c.1058N>T | p.Ser353Phe | p.S353F | O94782 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
USP1 | SNV | Missense_Mutation | novel | c.127C>G | p.Gln43Glu | p.Q43E | O94782 | protein_coding | tolerated(0.18) | benign(0.104) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | rs772351967 | c.962N>G | p.Tyr321Cys | p.Y321C | O94782 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.670N>G | p.Lys224Glu | p.K224E | O94782 | protein_coding | tolerated(0.82) | benign(0.033) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.1881N>T | p.Leu627Phe | p.L627F | O94782 | protein_coding | deleterious(0.04) | benign(0.376) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
USP1 | SNV | Missense_Mutation | novel | c.219G>C | p.Lys73Asn | p.K73N | O94782 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USP1 | insertion | In_Frame_Ins | novel | c.395_396insCGTTACTTCCAA | p.Asp131_Lys132insAsnValThrSer | p.D131_K132insNVTS | O94782 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
USP1 | insertion | Frame_Shift_Ins | novel | c.2072_2073insCTGCAGGTGCCCACCACCACGCCCGGCTAATTTTTTGTATTTT | p.Ser692CysfsTer15 | p.S692Cfs*15 | O94782 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
USP1 | SNV | Missense_Mutation | novel | c.748G>A | p.Glu250Lys | p.E250K | O94782 | protein_coding | tolerated(0.21) | benign(0.341) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-5510 | CHEMBL578741 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CLOFENOXYDE | CLOFENOXYDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GW7074 | CHEMBL72365 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CETRIMIDE | CETRIMIDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BENZIODARONE | BENZIODARONE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-4579 | CHEMBL584626 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | AMYLMETACRESOL | AMYLMETACRESOL | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BEXAROTENE | BEXAROTENE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DITHIAZANINE | DITHIAZANINE | |